期刊
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
卷 52, 期 4, 页码 191-210出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10408363.2015.1023430
关键词
Androgen receptor; biomarker; castration resistant prostate cancer; EpCAM; liquid biopsy; microfluidic; PSA
资金
- NIGMS [R01 GM63090]
- National Cancer Institute [R01 CA127727]
- Robert B. Goergen Prostate Cancer Foundation Young Investigator Award
- Department of Defense Physician Research Training Award [W81XWH-10-1-0483]
Substantial advances in the molecular biology of prostate cancer have led to the approval of multiple new systemic agents to treat men with metastatic castration-resistant prostate cancer (mCRPC). These treatments encompass androgen receptor directed therapies, immunotherapies, bone targeting radiopharmaceuticals and cytotoxic chemotherapies. There is, however, great heterogeneity in the degree of patient benefit with these agents, thus fueling the need to develop predictive biomarkers that are able to rationally guide therapy. Circulating tumor cells (CTCs) have the potential to provide an assessment of tumor-specific biomarkers through a non-invasive, repeatable liquid biopsy of a patient's cancer at a given point in time. CTCs have been extensively studied in men with mCRPC, where CTC enumeration using the Cellsearch (R) method has been validated and FDA approved to be used in conjunction with other clinical parameters as a prognostic biomarker in metastatic prostate cancer. In addition to enumeration, more sophisticated molecular profiling of CTCs is now feasible and may provide more clinical utility as it may reflect tumor evolution within an individual particularly under the pressure of systemic therapies. Here, we review technologies used to detect and characterize CTCs, and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据